Abstract: The disclosure relates to a protein-type nanoparticle for multi-specific antibody delivery, a preparation method, and its application. The protein-type nanoparticle includes a polyester and a protein with a hydrophobic domain, and the hydrophobic domain of the protein is bound with the polyester through hydrophobic interactions. The protein is at least one of albumin, globulin and cell wall protein. The protein-type nanoparticle of the present disclosure has excellent stability and biocompatibility. The protein-type nanoparticle is used to prepare a multi-specific antibody delivery platform (?Fc-NP) by binding anti-IgG-Fc antibody or anti-IgG-Fc antibody fragment, which can stably, quickly and easily bind to multiple specific antibodies through antigen-antibody interaction and enhance the therapeutic effect of specific antibodies.

Abstract: An electroluminescent device includes a first electrode and a second electrode facing each other; an emission layer disposed between the first electrode and the second electrode and including a plurality of quantum dots and a first hole transporting material having a substituted or unsubstituted C4 to C20 alkyl group attached to a backbone structure; a hole transport layer disposed between the emission layer and the first electrode and including a second hole transporting material; and an electron transport layer disposed between the emission layer and the second electrode.

Abstract: Polymeric nanoparticles comprising a defined set of biologically active agents that provide for targeted stimulation of non-responsive T cells, e.g. T cells involved in cancer, are provided.

Abstract: A non-aspirating dispenser containing a gel therein for delivery to a desired surface such as a medical article. More specifically, a gel that is dispensed in the form of droplets that are free of air or a gas therein and with reduced drift potential. The dispenser has a container having a flexible bag therein enclosing a thixotropic gel, and has a pressurized gas that is capable of exerting pressure on the bag and forcing the gel out of said bag in a steady stream upon pressing an actuator that is operatively connected to an ejection valve. The bag is free of propellants, and does not produce an aerosol. The gel is thixotropic and is utilized for keeping medical instruments moist in order to prevent soils present thereon from drying out, which can make reprocessing of medical instruments more difficult and less effective. The dispenser implemented at a point of use for transport or prior to delayed reprocessing in the reprocessing area.

Abstract: An aerogel carrying an active material, and a composite of a hydrogel and the aerogel are provided. The method for preparing the composite according to the present invention comprises the steps of preparing a plurality of aerogel particles having an active material in the pores, preparing a polymer solution in which a polymer is dissolved in a water-soluble solvent, preparing an aerogel/polymer dispersion by homogenizing after mixing the aerogel particles in the polymer solution, and preparing an aerogel/hydrogel composite carrier by mixing the dispersion with a crosslinking agent solution. According to the present invention, by producing a hydrogel composite in which a plurality of aerogel particles is distributed, a complex carrier in which oil and moisture can be carried simultaneously without any surfactant can be provided. Furthermore, a composite carrier having improved properties such as low density, high strength, high component content and stable desorption can be prepared.

Abstract: Described are compositions and methods relate to stable, high-payload, non-porous enzyme-containing coated granules with improved resistance to activity loss during steam pelleting.

Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.

Abstract: Liquid fabric care compositions that include certain fabric treatment adjuncts and/or water, where the compositions further include capsules characterized by substantially inorganic shells, for example silica-based shells. The present disclosure further relates to methods of making and using such compositions.

Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.

Abstract: The present invention relates to a composite preparation in a core tablet form, composed of an inner core containing rabeprazole as an effective ingredient; an outer layer portion including the bilayer structure of a sustained release layer and an immediate release layer and containing mosapride as an effective ingredient. The core tablet composite preparation according to the present invention is characterized by exerting sufficient pharmacological activity of rabeprazole and mosapride even upon administration of one tablet once a day.

Abstract: The invention relates to polyelectrolyte multilayer coatings and, methods for their preparation and application to substrates to enhance the bioactivity and corrosion protection of the substrates' surface. The invention is particularly suitable for coating substrates employed for medical applications, such as but not limited to medical implant devices for drug and/or biologics delivery in a patient. The substrate has a positive or negative charge. The polyelectrolyte multilayer coatings include at least a first polymer layer and a second polymer layer. The first polymer and second polymer have opposite charges. Each of the polymer layers is individually applied using a layer-by-layer such that an alternating charge multilayer coating is formed.

Abstract: Crystalline forms of emetine dihydrochloride (Compound I dihydrochloride) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms of Compound I dihydrochloride.

Abstract: The present invention provides methods and compositions comprising a particle comprising at least two different targeting agents that each bind a different protein receptor on a T cell surface.

Abstract: Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w/w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.

Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.

Abstract: Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.

Abstract: The present invention relates to the field of nanovectors for the delivery of active substances in the body, in particular for the treatment of tumours. In particular, the use of these nanovectors makes it possible to improve the pharmacokinetics of the active substances with a more selective delivery, for example in the tumour tissues.

Abstract: A baked food composition is provided that exhibits an unexpectedly loose, crunchy texture and multi-textural chew. The baked composition comprises a high amount of expanded inclusions and shredded root vegetable, which are agglomerated by a binder component comprising low amounts of oil, added sugar, and flour. The food composition is preferably free of hydrocoiloid gums and sugar syrups.

Abstract: A capsule for use in a smoking article includes a liquid sensory enhancing material; and a shell surrounding the liquid sensory enhancing material. The shell has an outer surface rendered hydrophobic by hydrophobic groups covalently bond to the outer surface of the shell. The shell may be rendered hydrophobic by reacting hydroxyl groups at outer surface of the shell with fatty acid halides to covalently attach fatty acid moieties to the surface of the capsule.

Abstract: A method of predicting the development of chronic lung allograft dysfunction (CLAD) in lung transplant patients using N-myc-interactor (NMI) as a biomarker and associated treatment thereof is presented. Also presented is a method of reducing the risk of CLAD by administering a therapeutic agent capable of increasing NMI in the patient. NMI is a critical regulator of epithelial-to-mesenchymal transition (EMT) and an important precursor to development of CLAD. NMI expression is reduced in CLAD patients and can be used as an early diagnostic biomarker to predict the development of CLAD. NMI can also be used as a drug target for a therapeutic to increase expression of NMI and treat chronic lung disease such as CLAD. Therapeutics comprising NMI protein or NMI gene can be used as potential treatments for chronic lung diseases such as CLAD.

Abstract: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of an immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.

Abstract: The present invention relates to a novel two-component system comprising acetylsalicylic acid (ASA) and which is particularly useful in providing an aqueous solution of ASA for immediate peroral administration.

Abstract: The present invention includes: 1) dissolving a first binder in a first solvent; 2) dissolving a dispersing agent in a solution in which the first binder is dissolved; 3) adding charcoal powder to the solution obtained in 2) and performing homogenous mixing to produce a dispersion in which the charcoal powder is bound to the first binder; 4) spray drying the dispersion obtained in 3) to produce a primary capsule from which the first solvent is removed; 5) dissolving a second binder and a softening agent in a second solvent; 6) homogeneously mixing a coloring agent and the dispersing agent with a solution in which the second binder and the softening agent are dissolved; 7) mixing the primary capsule with the solution obtained in 6) to produce a double capsule dispersion in which the primary capsule is bound to the second binder; and 8) spray-drying the double capsule dispersion to product a double capsule from which the second solvent is removed.

Abstract: The invention provides compositions and methods that comprise encapsulated silver diamine fluoride or other antimicrobial materials for use in treatment of dental caries, for example.

Abstract: Described herein are alcohol-resistant oral pharmaceutical compositions and dosage forms that exhibit reduced drug release in the presence of alcohol. The compositions comprise a substrate comprising a controlled release formulation of lorazepam and an alcohol-resistant coating surrounding the substrate.

Abstract: Decontamination of water using guar gum (GG) derivatives and applications thereof are provided herein. For water decontamination, guar gum cinnamate (GGCi) is fabricated into nanoparticles having a high surface area that facilitates the removal of water pollutants by adsorption. Owing to its high availability, low cost, slow biodegradability and high sustainability, GG is considered promising as a next generation cost effective green material for water decontamination.

Abstract: The disclosure relates, among others, to methods for preparing pharmaceutical compositions that can be provided to the subject in oral form, comprising as an active ingredient: a protein with a mass of 10 kilodalton or more, a nucleic acid molecule of 15 nucleotides or more, or a combination thereof. The one or more active ingredients are distributed in particles in a way that facilitates the uptake of the particles by the intestine and the release of the active ingredient(s) into the blood stream.

Abstract: Self-regulating, osmotic, floating gastroretentive compositions that provide extended release, delayed release, and/or delayed extended release of active pharmaceutical agents, as well as, optionally, immediate release of the same or a different active pharmaceutical agent, are provided here. The gastroretentive compositions of the disclosure comprise a swellable, extended release, multilayer core comprising a push layer and a pull layer; a water-insoluble permeable elastic membrane surrounding the multilayer core; and an orifice (e.g., a laser-drilled orifice, a manually drilled orifice) on the pull-layer side of the dosage form. The gastric retention of the composition is controlled by rapid floating of the composition and expansion of the membrane.

Abstract: The disclosure describes imaging and therapy techniques comprising nanodroplets. More particularly, aspects of the disclosure relate to the use of nanodroplets to modify nanobubbles or microbubbles to provide improved imaging and/or therapeutic techniques and compositions.

Abstract: The present disclosure relates to use of Rivastigmine in the preparation of an anti-radiation medicament, and belongs to the field of medical technology. The present disclosure provides use of Rivastigmine in the preparation of an anti-radiation medicament. Researches show that Rivastigmine significantly promoted the proliferation of Lgr5+ stem cells receiving 10 Gy radiation (after being irradiated with 10 Gy radiation for 10 d, Lgr5+ stem cells cultured in a Rivastigmine-containing culture solution had an increment 14.2 times of that of the Lgr5+ stem cells cultured in a Rivastigmine-free culture solution). Rivastigmine also significantly reduced the mortality of mice after being irradiated with 10 Gy radiation (after receiving 10 Gy whole body irradiation, all the mice not intraperitoneally injected Rivastigmine died within 10 d; and for the mice intraperitoneally injected Rivastigmine, the survival rate of the mice was still greater than 40% 30 d later), and thus might have good radiation-proof effect.

Abstract: Provided are a modified mesenchymal stem cell and culture supernatant thereof, and a pharmaceutical composition comprising said cell or culture supernatant thereof. The mesenchymal stem cell is capable of expressing: (1) a first protein, which is selected from FGF21 or a variant thereof, or a first fusion protein comprising the FGF21 or the variant thereof and (2) a second protein, which is selected from GLP-1 or a variant thereof or a second fusion protein comprising the GLP-1 or the variant thereof. Also provided is the use of the modified mesenchymal stem cell and culture supernatant thereof, and the pharmaceutical composition comprising said cell or culture supernatant thereof in the treatment of metabolic diseases and in the preparation of a medicament for treating metabolic diseases.

Abstract: There is provided a method for producing hydroxypropyl methyl cellulose acetate succinate (HPMCAS), including an esterification step of reacting hydroxypropyl methyl cellulose with an acetylating agent and a succinoylating agent in the presence of an aliphatic carboxylic acid in a kneader reactor equipped with two or more stirring blades rotating around their own axes and orbitally revolving, to obtain a reaction product solution containing HPMCAS; a precipitation step of precipitating the HPMCAS by mixing the reaction product solution with water to obtain a suspension of the precipitated HPMCAS; and a washing and recovery step of washing the HPMCAS in the suspension and recovering the washed HPMCAS. Further, there is provided HPMCAS having yellowness at 20° C. of 15.0 or less, as determined in a 2% by mass solution of the HPMCAS in a mixed solvent of dichloromethane, methanol and water in a mass ratio of 44:44:10.

Abstract: The present application relates to polymer microparticle-metal nanoparticle composites, to methods of preparing polymer microparticle-metal nanoparticle composites and to uses of such composites. The methods comprise introducing into a microfluidic device, a composition comprising: a cationic metal nanoparticle precursor; a polymer microparticle precursor that comprises a plurality of photopolymerizable groups; and a photoreducer-photoinitiator; then irradiating the composition under conditions to simultaneously reduce the cationic metal and polymerize the photopolymerizable groups to obtain the composite.

Abstract: The present invention relates to pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride. More particularly, the present invention relates to a tablet composition comprising trifluridine, tipiracil hydrochloride and one or more pharmaceutically acceptable excipients and process for preparing such compositions.

Abstract: A water-soluble polyurethane derived from: polyethylene glycol, polyethylene glycol-block-polypropylene glycol-block-polyethylene glycol polymer, polypropylene glycol-block-polyethylene glycol-block-polypropylene and mixtures thereof, 1,1?-Carbonyldiimidazole, polyamine and mixtures thereof.

Abstract: The invention discloses odor masking formulations for stench natural compounds, selected from the extracts, fraction and pure phytochemicals that are produced in combination with a natural or synthetic hydrocolloid polymer gum(s). The invention further discloses novel process of producing the odor and taste masking formulations. The invention also discloses taste masking formulations of valerian extracts with no characteristic stench odor & or negligible stench odor in combination with natural hydrocolloid gum such as guar gum, acacia or other polymers. The invention further discloses method of reducing insomnia, anxiety, Attention Deficit Disorder (ADD), Chronic Fatigue Syndrome (CFS) using odor masking formulation of the current invention. Importantly, the said odor masked formulation of the present disclosure helps in improving sleep cycle and helps in efficient functioning of brain.

Abstract: A mineralization agent, including, by weight: 5-50% of a film-forming protein, 5-40% of an amelogenin peptide, 5-30% of a water-soluble phosphate, 4-20% of a tris(2-carboxyethyl) phosphine hydrochloride, and 1-10% of a pH regulator. The film-forming protein is selected from the group consisting of lysozyme, bovine serum protein, insulin, ?-lactalbumin, or a mixture thereof.

Abstract: The present invention aims to provide a preparation expected to improve the bitter taste of an organic acid salt of vonoprazan and permit rapid dissolution of the organic acid salt of vonoprazan after administration. The present invention provides a preparation containing fine granules or granules containing (1) a core granule containing an organic acid salt of vonoprazan, (2) an intermediate layer containing the same organic acid as the organic acid forming the salt of vonoprazan in (1), or a salt thereof, and (3) a coating layer containing a water-insoluble polymer.

Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.

Abstract: Ultraviolet radiation sun protective compositions are reported which feature micronized metal oxide inorganic particles selected from zinc oxide, titanium dioxide and mixtures thereof, the inorganic particles being coated with an adduct of a hydroxy cinnamate and a silanol, amounts of the adduct to the inorganic particles being in a relative weight ratio of 1:200 to 1:4.

Abstract: Embodiments of the synthesis, radiolabeling and biological applications of an activatable tracer that undergoes intramolecular cyclization and aggregation upon activation by cleavage of a blocking moiety are provided. The probes of the disclosure allow for target-controlled self-assembly of small molecules in living subjects for imaging and drug delivery. The aggregated nanoprobes of the disclosure may be detectable optically, by PET detection, magnetic resonance imaging, and the like depending on the detectable reporter attached to the nanoprobe.

Abstract: In one aspect, the present disclosure provides microparticles that are configured to release a first drug over a first time period and to release a second drug over a second time period, wherein a lag period of substantially no drug release occurs between the first and second time periods. In other aspects, the present disclosure pertains to the use of such microparticles in delivery systems and methods of treatment. In another aspect, the present disclosure pertains to drug delivery systems that comprising a folded inflatable drug delivery balloon that comprises folds and microparticles positioned within the folds.

Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising carbidopa and levodopa.

Abstract: An improved heroin conjugate vaccine is detailed; to accomplish this task the systematic exploration of twenty vaccine formulations with varying combinations of carrier proteins and adjuvants were undertaken. In regard to adjuvants, a Toll-like receptor 9 (TLR9) agonist and a TLR3 agonist in the presence of alum were explored. The vaccine formulations containing TLR3 or TLR9 agonist alone-elicited strong anti-heroin antibody titers and blockade of heroin-induced antinociception when formulated with alum; however, a combination of TLR3 and 9 adjuvants did not result in improved efficacy. Investigation of stability of the two lead formulations revealed that the TLR9 but not the TLR3 formulation was stable when stored over 30 days. Furthermore, mice immunized with the TLR9+alum heroin vaccine gained significant protection from lethal heroin doses, suggesting that this vaccine formulation is suitable for mitigating the lethal effects of heroin, even following long-term storage at room temperature.

Abstract: Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are also provided.

Abstract: The present invention relates to the use for ore beneficiation, of at least one derivative of alkoxylated (polyester)amine. The present invention also relates to the flotation pulp and the tailings comprising said product useful for ore beneficiation.

Abstract: Loose particulate materials can be problematic in various aspects. For example, loose particulate materials may generate dust or be difficult to consolidate together. Fines in loose particulate materials may also be an issue. Coated particulates may alleviate some of the foregoing issues. Suitable coated particulates may comprise a particulate material comprising sand or a ceramic, and a polysaccharide composition coated upon the particulate material, the polysaccharide composition comprising a functionalized polysaccharide. Other particulate materials such as wood chips and animal litter particulates may be coated with functionalized polysaccharides to achieve similar advantages.

Abstract: A composition according to an embodiment of the present disclosure includes a banaba leaf extract, a guava leaf extract or a mixture thereof. The composition inhibits photooxidation of A2E due to blue light, inhibits a death of retinal pigment epithelial cells induced by blue light, and inhibits a damage to outer nuclear layers of visual cells in an animal model with blue light-induced macular degeneration, and thus can be beneficially used as a composition for preventing or treating macular degeneration and as a health functional food for preventing or alleviating macular degeneration.

Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising carbidopa and levodopa.

Abstract: Liquid formulations containing picosulfate and magnesium citrate are provided. The compositions can include one or more precipitation inhibitors such as carboxylic acids (e.g., malonic acid), soluble anionic polymers and ammonium salts. The formulations are useful to treat constipation or for the clearance of the bowel prior to X-ray examination, endoscopy or surgery.